Company: REVB
Filing Date: 2025-06-09
Form Type: DEF 14A
Source: 0000950170-25-083815
Chunk: 13

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-06-09
Form: DEF 14A
Chunk 13
---
, resignation or removal.

All of our directors bring to the Board signiﬁcant leadership experience derived from their professional experience and service as executives or board members of other corporations. The process undertaken by the Nominating and Corporate Governance Committee in recommending qualiﬁed director candidates is described below under “Corporate Governance.” Certain individual qualiﬁcations and skills of our directors that contribute to the Board’s effectiveness as a whole are described under “Information about Our Directors.”

<div align='center'>THE BOARD OF DIRECTORSUNANIMOUSLYRECOMMENDS THAT YOU VOTE “FOR” THE NOMINEE LISTED ABOVE AS DIRECTOR OF THE COMPANY.

8</div>

Information about Our Directors Set forth below is certain information regarding the directors of the Company, including the nominees for election at the Annual Meeting and their ages as of May 29 , 2025 .

| Name                      |     | Age |     | Class |     | Director Since |     | Position                                       |
| Jennifer Carver, BSN, MBA |     |  71 |     | A     |     |           2020 |     | Independent Director                           |
| James Rolke               |     |  56 |     | B     |     |           2020 |     | Chairman, Director and Chief Executive Officer |
| Jess Roper                |     |  60 |     | B     |     |           2023 |     | Independent Director                           |
| Lakhmir Chawla, M.D.      |     |  54 |     | C     |     |           2023 |     | Independent Director                           |

Class A Director Continuing in Office Until the 2026 Annual Meeting Jennifer Carver, BSN, MBA — Director. Ms. Carver has been a director of the Company since May 2020. Ms. Carver brings over 20 years of industry experience with a focus on small biotech companies and their evolution from early development through commercialization. From 2020 to 2021, Ms. Carver has served as Chief Operating Officer at Kartos Therapeutics (Kartos). Prior to Kartos from 2014, Ms. Carver was employed at La Jolla Pharmaceutical Company in various leadership roles providing leadership through the clinical development, approval and launch of Giapreza and serving as Chief Operating Officer from 2017 to 2019. Prior to La Jolla, Ms. Carver held positions at Spectrum Pharmaceuticals and Allos Therapeutics, leading